- Condition: Healthy Volunteers
Interventions: Drug: Warfarin; Drug: Dexpramipexole
Sponsors: Biogen Idec; Biogen Idec
Not yet recruiting - verified May 2012 - Conditions: Osteoarthritis of the Knee; Coagulopathy
Intervention: Drug: PENNSAID (diclofenac sodium solution topical)
Sponsors: Arthritis Treatment Center, Maryland; Nathan Wei, MD, FACP, FACR:; Covidien; Arthritis Treatment Center, Maryland
Recruiting - verified February 2012 - Condition: Solid Tumors
Interventions: Drug: tivantinib; Drug: omeprazole; Drug: s-warfarin; Drug: caffeine; Dietary Supplement: vitamin K; Drug: digoxin; Drug: midazolam
Sponsors: Daiichi Sankyo Inc.; Daiichi Sankyo Inc.; Medpace, Inc.
Recruiting - verified January 2012 - Condition: Coagulation Delay
Interventions: Dietary Supplement: phytonadione; Drug: none-control group
Sponsors: James A. Haley Veterans Administration Hospital; James A. Haley Veterans Administration Hospital
Recruiting - verified December 2011 - Conditions: Drug Interactions; BRAF; Cancer
Interventions: Drug: Warfarin; Drug: Ketoconazole; Drug: Gemfibrozil; Drug: GSK2118436 150mg; Drug: GSK2118436 75mg
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Recruiting - verified February 2012 - Conditions: Solid Tumor; Hematological Malignancy
Intervention: Drug: Belinostat, Warfarin
Sponsors: Spectrum Pharmaceuticals, Inc; Spectrum Pharmaceuticals, Inc; TopoTarget A/S
Recruiting - verified March 2011 - Condition: Warfarin Initiation
Intervention: Device: Warfarin GenoSTAT Test
Sponsors: Iverson Genetic Diagnostics, Inc.; Iverson Genetic Diagnostics, Inc.
Recruiting - verified May 2012 - Conditions: Atrial Fibrillation; Stroke
Interventions: Device: WATCHMAN Device; Drug: Warfarin
Sponsors: Atritech; Atritech
Recruiting - verified April 2012 - Condition: Pulmonary Hypertension
Intervention: Drug: Warfarin
Sponsors: University of North Carolina, Chapel Hill; University of North Carolina, Chapel Hill; National Heart, Lung, and Blood Institute (NHLBI)
Recruiting - verified November 2011 - Condition: Thromboembolism
Interventions: Other: Pharmacogenetic Warfarin Initiation; Other: Clinical Warfarin Initiation (non-pharmacogenetic); Other: Pharmacogenetic Warfarin Initiation; Other: Clinical Warfarin Initiation (non-pharmacogenetic)
Sponsors: Washington University School of Medicine; Washington University School of Medicine; Intermountain Health Care, Inc.; University of Utah; Hospital for Special Surgery, New York; National Heart, Lung, and Blood Institute (NHLBI)
Recruiting - verified August 2011 - Conditions: Venous Thromboembolism; Deep Vein Thrombosis; Pulmonary Embolism; Thromboembolism; Venous Thrombosis
Interventions: Drug: edoxaban tosylate(DU-176b); Drug: low molecular weight heparin/unfractionated heparin; Drug: warfarin
Sponsors: Daiichi Sankyo Inc.; Daiichi Sankyo Inc.
Recruiting - verified February 2012 - Conditions: Atrial Fibrillation; Deep Vein Thrombosis; Dilated Cardiomyopathies
Interventions: Behavioral: Financial Incentive and Med-eMonitor; Device: 2Med-eMonitor
Sponsors: University of Pennsylvania; University of Pennsylvania
Recruiting - verified August 2011 - Conditions: Atrial Fibrillation; Deep Vein Thrombosis; Pulmonary Embolism; Artificial Heart Valve
Interventions: Other: Genotype-guided dose determination; Other: Non-genotype guided warfarin dosing
Sponsors: University of North Carolina, Chapel Hill; University of North Carolina, Chapel Hill; UNC Institute for Pharmacogenomics and Individualized Therapy
Recruiting - verified February 2012 - Conditions: Stroke; Venous Thrombosis; Atrial Fibrillation; Atrial Flutter
Interventions: Behavioral: Genotype-guided dosing algorithm for warfarin; Behavioral: Clinical-guided dosing algorithm for warfarin
Sponsors: National Heart, Lung, and Blood Institute (NHLBI); National Heart, Lung, and Blood Institute (NHLBI); Bristol-Myers Squibb
Recruiting - verified May 2012 - Condition: Venous Thromboembolism
Intervention:
Sponsors: Ottawa Hospital Research Institute; Ottawa Hospital Research Institute; Heart and Stroke Foundation of Ontario
Recruiting - verified June 2011 - Conditions: Deep Vein Thrombosis; Venous Thrombosis; Postphlebitic Syndrome; Venous Thromboembolism; Post Thrombotic Syndrome
Intervention: Drug: Recombinant tissue plasminogen activator (rt-PA)
Sponsors: Washington University School of Medicine; Washington University School of Medicine; McMaster University; Ontario Clinical Oncology Group (OCOG); National Heart, Lung, and Blood Institute (NHLBI); Bacchus Vascular; BSN Medical Inc; Genentech; MEDRAD Interventional/Possis; Mid America Heart Institute; Society of Interventional Radiology Foundation; Massachusetts General Hospital
Recruiting - verified May 2012 - Condition: Venous Thrombosis
Interventions: Drug: Enoxaparin; Drug: warfarin; Drug: Placebo for apixaban; Drug: Placebo for enoxaparin; Drug: Placebo for warfarin; Drug: apixaban
Sponsors: Bristol-Myers Squibb; Bristol-Myers Squibb; Pfizer
Recruiting - verified October 2010 - Conditions: Atrial Fibrillation; Atrial Flutter; Stroke; Embolism, Systemic Arterial; Major Bleeding
Interventions: Drug: Oral Anticoagulation; Drug: Oral Anticoagulation
Sponsors: Biotronik, Inc.; Biotronik, Inc.
Recruiting - verified January 2012 - Condition: Heart Valve Disease
Interventions: Device: On-X valve using reduced anticoagulation; Device: On-X Valve with Standard Coumadin Therapy
Sponsors: Medical Carbon Research Institute, LLC; Medical Carbon Research Institute, LLC
Recruiting - verified June 2011
 |
Coumadin Clinical Trials |
